The gold standard chemotherapy for GBM is temozolomide (TMZ), however, the impact of temozolomide in the TME modulation remains unclear, with some reports suggesting its potential use as an enhancer of immune activation in regimens combining TMZ with immunotherapy (105), whilst others have suggested its contribution to the TME’s immunosuppressive behavior through Treg enrichment, partially reversible through IL-2 (27, 106). Here, IL2 is linked to glioblastoma.